Journal of Bronchology & Interventional Pulmonology:
Safety of Ultrasound-guided Small-Bore Chest Tube Insertion in Patients on Clopidogrel
Dammert, Pedro MD; Pratter, Melvin MD; Boujaoude, Ziad MD
Division of Pulmonary and Critical Care Medicine, Cooper Medical School of Rowan University, Cooper University Hospital, Camden, NJ
Disclosure: There is no conflict of interest or other disclosures.
Reprints: Ziad Boujaoude, MD, 3 Cooper Plaza, Suite 312, Camden, NJ 08103 (e-mail: firstname.lastname@example.org).
Received November 29, 2012
Accepted December 4, 2012
Background: The safety of small-bore chest tubes insertion with ultrasound (US) guidance has been well demonstrated in patients not receiving antiplatelet therapy. Given the current widespread use of these agents, pulmonologists frequently encounter patients on this therapy and requiring drainage of the pleural space. The use of these agents clearly increases the risk of bleeding, but it is not always possible to stop this therapy before the procedure, especially in patients requiring urgent drainage and those with coronary stents. The purpose of this study is to report our experience on the safety of US-guided small-bore chest tube placement in patients receiving clopidogrel.
Methods: This was a retrospective review of the charts of adult patients who underwent small-bore chest tube insertion by the pulmonary service while on clopidogrel. Data collected included patient’s and effusion characteristics, indication for clopidogrel and for the procedure, and any significant bleeding complication defined as hemothorax, chest wall hematoma, a reduction in hemoglobin of >2 g/dL, or any bleeding requiring blood transfusion, surgery, or chest tube insertion. US of the chest was performed before insertion but did not include Doppler study of intercostal arteries. Lateral insertion at or anterior to the posterior axillary line was the preferred choice when possible.
Results: Forty-three procedures were performed in 30 patients. Seventy percent were male with a mean age of 71 years. The indications for clopidogrel were coronary stents (50%), acute coronary syndrome (27%), prevention of graft occlusion after coronary artery bypass graft (CABG) (13%), femoral stent or endarterectomy (7%), and carotid endarterectomy (3%). The etiology of the effusions was post-CABG (43%), heart failure (17%), end-stage renal disease (13%), pneumothorax (10%), and others (17%). The procedures were therapeutic in 41 cases and diagnostic in 2. The indications for the procedure were respiratory distress (65%), respiratory failure (23%), and pneumothorax (7%). Fifteen procedures (35%) were performed in 10 patients in the ICU and 6 of them were mechanically ventilated. Nine patients were obese based on body mass index. Neither significant bleeding nor other minor complications were seen.
Conclusions: The insertion of small-bore chest tube in patients receiving clopidogrel can be safe if performed by experienced operators and by using US guidance along with lateral insertion site, which has the lowest risk of lacerating the intercostal arteries.
Pleural space drainage using small-bore chest tubes inserted under ultrasound (US) guidance has gained increased acceptance in recent years and in many institutions it has replaced large-bore chest tubes for most indications.1 Several studies have demonstrated the safety and efficacy of US-guided small-bore chest tubes with a reported rate of minor bleeding between 1% and 2%.2,3 This data on bleeding complications, however, is primarily on patients without significant coagulopathy and who are not receiving antiplatelet therapy. Not surprisingly, given the current widespread use of antiplatelet agents, pulmonologists are now encountering patients on this therapy who clinically require urgent pleural drainage for either large pleural effusion or occasionally pneumothorax.
Clopidogrel, a thienopyridine compound that profoundly inhibits adenosine diphosphate-induced platelet aggregation,4 is of particular concern. Its efficacy to prevent thrombosis in patients with acute coronary syndromes and coronary artery stents is well established,5,6 but its presence clearly increases the risk of bleeding from surgical procedures. Reflecting the risk of bleeding, a common practice is to discontinue clopidogrel for 5 to 7 days before any invasive procedure. This approach, however, is problematic in patients with an urgent need for pleural space drainage and in patients who have a strong contraindication to stopping clopidogrel (eg, patients with recent placement of coronary stents where the discontinuation has been associated with high risk of thrombosis).7
It has become our practice to proceed with the insertion of a small-bore chest tube under US guidance in patients on clopidogrel when it either cannot be safely stopped or when it is not clinically feasible to wait 5 to 7 days before draining the pleural space. The purpose of this study is to report our experience on the safety of this approach in patients on clopidogrel.
PATIENTS AND METHODS
The study was approved by the Institutional Review Board and was designed as a retrospective review.
A review of the medical records of patients that underwent small-bore chest tube insertion under US guidance by the Pulmonary and Critical Care Division at Cooper University Hospital from January 2010 to September 2012 was carried out. Patients were included in the study if they were at least 18 years old and were taking clopidogrel for at least 5 days and up to 24 hours before the procedure. Data collected included patient’s age, sex, weight, height, serum creatinine, platelet count and coagulation studies, preprocedure and postprocedure hemoglobin, indications for the procedure and for clopidogrel, volume, and underlying cause of effusion and bleeding complications including the need for postprocedure transfusion.
US-guided Chest Tube Insertion
At our institution the insertion of small-bore chest tubes under US guidance is usually performed by a Pulmonary and Critical Care fellow under the direct supervision of an interventional pulmonologist. Our standard procedure is to first evaluate the chest with US (Sonosite M-turbo) with a Phased Array transducer (Sonosite P21X/5-1MHZ) identifying the diaphragm, the effusion, and the pleural line in case of a pneumothorax. The insertion site is identified and marked as close as possible to the posterior axillary line in patients with effusions and in the second intercostal space at the midclavicular line for pneumothorax. Doppler studies of the intercostal arteries are not routinely performed. The site is then prepared, draped, and local anesthesia with 1% lidocaine is administered. A small incision is made using a number 11 scalpel. The catheter is inserted using either a standard Seldinger technique (over a guidewire) or a modified Seldinger (over a needle), depending on the size of tube utilized. Three different catheters were used based on operator preference: 8 Fr Arrow catheter (Arrow International, Reading, PA), 14 Fr Wane pigtail catheter (Cook Medical, Bloomington, IN), and 16 Fr Navarre pigtail catheter (C.R. Bard, Covington, GA).
Outcomes and Definitions
The primary parameter of the study was the incidence of any significant bleeding complication. Significant bleeding complications were defined as a reduction in hemoglobin of >2 g/dL after chest tube insertion, hemothorax, development of a chest wall hematoma or any bleeding requiring blood transfusion, surgery, additional chest tube insertion, or intensive care unit (ICU) admission. Secondary outcomes were the presence of any other local bleeding not meeting the above criteria.
Descriptive statistical analysis was expressed in means, percentages, and frequency.
Baseline demographics and pleural effusions characteristics are shown in Tables 1 and 2, respectively. Forty-three procedures were performed in 30 patients who met inclusion criteria. Patients were predominantly male (70%), with a mean age of 71±10 years. The mean body mass index was 28 (range, 18 to 39). Nine patients were obese with body mass index ≥30. The indications for clopidogrel were coronary stents (50%), acute coronary syndrome (27%), prevention of graft occlusion after coronary artery bypass graft (CABG) (13%), femoral stent or endarterectomy (7%), and carotid endarterectomy (3%). The etiologies of the effusions were post-CABG (48%), heart failure (18.5%), end-stage renal disease (15%), and others (17%). Forty-one procedures (95%) were therapeutic and 2 (5%) were diagnostic. The indications for procedure were respiratory distress (28, 65%), respiratory failure (10, 23%), and pneumothorax (3, 7%). The 2 diagnostic procedures were performed for suspected infection of pleural space.
Twenty-seven procedures were performed with 14 Fr chest tubes, 11 with 8 Fr tubes, and 5 with 16 Fr tubes. The Seldinger technique was used in 29 procedures and modified Seldinger in 14. Fifteen procedures (35%) were performed on 10 patients in the ICU, 6 of them were on positive pressure mechanical ventilation. The amount of fluid drained during first 24 hours was recorded in 33 procedures; the mean volume removed was 1183 mL (range, 500 to 2500 mL).
Most of the patients (91%) were receiving aspirin in addition to clopidogrel. All the patients had a platelet count >50,000/μL and an INR <1.5, with 1 exception where the INR was 1.7. Nine patients had a serum creatinine >2.0 mg/dL but only 1 was >6 mg/dL.
No significant bleeding or any other complications were seen. Preprocedure and postprocedure hemoglobin was recorded in 81% of the cases. No patient had a drop of >1.2 g/dL. In patients who did not have postprocedure hemoglobin, no bleeding events were described in the charts.
The key finding of this study is that when performed by experienced operators, US-guided placement of a small-bore chest tube is safe even in patients on clopidogrel. In the 43 reviewed procedures, there was no occurrence of clinically significant bleeding. This is important because clopidogrel is commonly used to prevent thrombosis in acute coronary syndromes and after coronary stent placement. It is also used to prevent CABG graft closure and for secondary prevention in coronary artery disease, stroke, and peripheral vascular disease. Given the high prevalence of these disorders, it is expected to be a common occurrence for pulmonologists to see patients on this drug who simultaneously need drainage of the pleural space.8
It is important to recognize that the lack of bleeding seen with small-bore chest tube insertion should not be extrapolated to other situations involving invasive procedures. Clopidogrel has been associated with an increased bleeding risk during gastrointestinal procedures (particularly polypectomy),9 and in patients undergoing CABG.10 Furthermore a recent report by Ernst et al11 showed that patients on clopidogrel had an 89% rate of bleeding after a transbronchial lung biopsy compared with a rate of 3.4% in the control group. One study reported that the rate of major gastrointestinal bleeding and bleeding at the site of an arterial puncture in patients on clopidogrel is much higher compared with patients on aspirin alone.12
It is standard practice to discontinue clopidogrel for 5 to 7 days before an invasive procedure.13 This was not possible in our patient group, which was comprised of patients with pleural effusions causing respiratory distress or respiratory failure in whom the procedure could not be delayed or patients with coronary stents where discontinuing therapy would have increased significantly the risk of stent thrombosis.14,15
The risk of chest tube insertion can be diminished by following evidence-based precautions and avoiding situations that involve a known increased risk of complications: they include using US to mark the insertion site and avoiding the procedure in patients on anticoagulation or with bleeding diathesis (PT or PTT greater than twice the midpoint of the normal range, platelet count <25,000 platelets/mm3, or a serum creatinine concentration >6 mg/dL).16,17
Adhering to these measures certainly contributed to the low bleeding complications rate observed in our study but there are 4 additional factors that we believe were relevant to the lack of complications. The first factor is the lateral insertion site at or anterior to the posterior axillary line. This location carries the lowest risk of lacerating the intercostal arteries, the vessels most likely to be the source of excessive bleeding during chest tube insertion. This is directly related to the anatomy of these arteries. In children, the intercostal arteries are usually concealed behind the lower ribs and are not directly accessible to extrathoracic puncture. These arteries tend to sag below the lower rib borders with age which increase their vulnerability; however, this tendency is less prominent with the increasing distance from the spinal column and the arteries are usually protected, even in older individuals, at the point where the ribs angle forward.18,19 The second factor that we believe minimized the risk of complications was the fact that all the procedures were performed under the direct supervision of pulmonologists with extensive experience with pleural procedures. The third factor was the routine use of US guidance to choose the site of insertion. Fourth, was the fact that we avoided the use of large-bore surgical chest tubes and instead exclusively used small-bore tubes that were inserted using Seldinger or modified Seldinger technique.
This study adds to the recent small, but mounting body of literature that supports the safety of performing selected procedures on clopidogrel. Stather et al20 reported no significant bleeding from EBUS-TBNA in a retrospective review of 12 cases. Recent data show that thoracotomy can be performed safely in patients taking clopidogrel.21
Our results are also in agreement with 2 recent publications by Zalt el al22 and Abouzgheib et al23 of small series of patients on clopidogrel who underwent US-guided thoracentesis and small-bore chest tube placement, respectively, without bleeding complications. Our study also highlights that even in patients in the ICU and obese patients, in whom positioning for the procedure can be challenging, no complications occurred.
Our study has limitations: first, it was retrospective and involved a single center; second, the study size was not large enough to detect the bleeding rate of 1% that has been reported in patients not taking clopidogrel; finally, as all the procedures were performed or supervised by highly experienced operators, the results cannot be extrapolated to less experienced operators.
Nevertheless, our findings strongly indicate that US-guided small-bore chest tube insertion in patients on clopidogrel can be safely performed by experienced operators using the lateral insertion site.
1. Light RW. Pleural controversy: optimal chest tube size for drainage. Respirology. 2011;16:244–248
2. Davies HE, Merchant S, McGown A. A study of the complications of small bore ‘Seldinger’ intercostal chest drains. Respirology. 2008;13:603–607
3. Horsley A, Jones J, White J, et al. Efficacy and complications of small-bore, wire-guided chest drains. Chest. 2006;130:1857–1863
4. Verstraete M, Zoldheyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856–884
5. Yusuf S, Zhao F, Mehta Sr, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
6. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999;99:2364–2366
7. Lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stent. JAMA. 2005;293:2126–2130
8. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation
9. Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol. 2009;54:2261–2276
10. Kapetanakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation. 2006;113:1667–1674
11. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006;129:734–737
12. Yusuf S, Zhao F, Mehta Sr, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
13. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):e326S–e3250
14. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–754
15. Ferreira-González I, Marsal JR, Ribera A, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010;122:1017–1025
16. Duncan DR, Morgenthaler TI, Ryu JH, et al. Reducing iatrogenic risk in thoracentesis: establishing best practice via experiential training in a zero-risk environment. Chest. 2009;135:1315–1320
17. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;31:164–171
18. Yoneyama H, Arahata M, Temaru R, et al. Evaluation of the risk of intercostal artery laceration during thoracentesis in elderly patients by using 3D-CT angiography. Intern Med. 2010;49:289–292
19. Carney M, Ravin CE. Intercostal artery laceration during thoracocentesis: increased risk in elderly patients. Chest. 1979;75:520–522
20. Stather DR, MacEachern P, Chee A, et al. Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: a report of 12 consecutive cases. Respiration. 2012;83:330–334
21. Certfolio RJ, Minnich DJ, Brayant AS, et al. General thoracic surgery is safe in patients taking clopidogrel (plavix). J Thorac Cardiovasc Surg. 2012;140:970–976
22. Zalt MB, Bechara RI, Parks C, et al. Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis. J Bronchol Intervent Pulmonol. 2012;19:284–287
23. Abouzgheib W, Shweihat YR, Meena N, et al. Is chest tube insertion with ultrasound guidance safe in patients using clopidogrel? Respirology. 2012;17:1222–1224
ultrasound; chest tube; bleeding; antiplatelet; clopidogrel; pleural effusion; pneumothorax
© 2013 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.